Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Identifying genetic markers enriched by brain imaging endophenotypes in Alzheimer's disease.

Tytuł:
Identifying genetic markers enriched by brain imaging endophenotypes in Alzheimer's disease.
Autorzy:
Kim M; Department of Artificial intelligence, Catholic University of Korea, Bucheon, Republic of Korea.
Wu R; School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, USA.
Yao X; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
Saykin AJ; Indiana Alzheimer Disease Center and Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA.
Moore JH; Department of Computational Biomedicine, Cedars Sinai Medical Center, West Hollywood, USA.
Shen L; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. .
Corporate Authors:
Alzheimer’s Disease Neuroimaging Initiative
Źródło:
BMC medical genomics [BMC Med Genomics] 2022 Aug 01; Vol. 15 (Suppl 2), pp. 168. Date of Electronic Publication: 2022 Aug 01.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central
MeSH Terms:
Alzheimer Disease*/diagnostic imaging
Alzheimer Disease*/genetics
Brain/diagnostic imaging ; Endophenotypes ; Genetic Markers ; Genetic Predisposition to Disease ; Genome-Wide Association Study/methods ; Humans ; Neuroimaging ; Polymorphism, Single Nucleotide
References:
Nat Genet. 2013 Dec;45(12):1452-8. (PMID: 24162737)
JAMA. 2011 Jan 19;305(3):275-83. (PMID: 21245183)
Transl Psychiatry. 2018 May 18;8(1):99. (PMID: 29777097)
BMC Med Genomics. 2019 Sep 9;12(1):128. (PMID: 31500627)
Mol Neurodegener. 2017 May 26;12(1):43. (PMID: 28549481)
Biomed Pharmacother. 2019 Jul;115:108903. (PMID: 31054508)
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31. (PMID: 22252372)
Nature. 2015 Feb 19;518(7539):365-9. (PMID: 25693568)
Nat Genet. 2019 Mar;51(3):404-413. (PMID: 30617256)
Arch Gen Psychiatry. 2006 Feb;63(2):168-74. (PMID: 16461860)
PLoS Genet. 2018 Nov 2;14(11):e1007427. (PMID: 30388101)
PLoS One. 2016 Feb 26;11(2):e0148717. (PMID: 26919393)
Acta Neuropathol. 2020 May;139(5):937-940. (PMID: 32112171)
Hum Mol Genet. 2018 May 1;27(R1):R22-R28. (PMID: 29522091)
Front Aging Neurosci. 2020 Feb 04;12:16. (PMID: 32116649)
Alzheimers Dement. 2013 Sep;9(5):e111-94. (PMID: 23932184)
Psychiatry Res. 2019 Sep;279:376-377. (PMID: 30717989)
Proc IEEE Inst Electr Electron Eng. 2020 Jan;108(1):125-162. (PMID: 31902950)
Nat Genet. 2019 Mar;51(3):414-430. (PMID: 30820047)
Neurology. 2016 Aug 2;87(5):489-96. (PMID: 27371493)
Am J Hum Genet. 2007 Sep;81(3):559-75. (PMID: 17701901)
Neuroimage. 2010 Nov 15;53(3):1051-63. (PMID: 20100581)
PLoS One. 2017 Jun 26;12(6):e0179677. (PMID: 28650998)
Grant Information:
R01 AG058854 United States AG NIA NIH HHS; U01 AG024904 United States AG NIA NIH HHS; U01 AG068057 United States AG NIA NIH HHS; U19 AG024904 United States AG NIA NIH HHS; R01 AG071470 United States AG NIA NIH HHS; P30 AG072976 United States AG NIA NIH HHS; R01 LM013463 United States LM NLM NIH HHS; P30 AG010133 United States AG NIA NIH HHS; U24 AG021886 United States AG NIA NIH HHS
Contributed Indexing:
Keywords: Brain imaging genetics; Genome-wide association study; Imaging-diagnosis map; Imaging-genetics map
Substance Nomenclature:
0 (Genetic Markers)
Entry Date(s):
Date Created: 20220801 Date Completed: 20220803 Latest Revision: 20240323
Update Code:
20240323
PubMed Central ID:
PMC9344647
DOI:
10.1186/s12920-022-01323-8
PMID:
35915443
Czasopismo naukowe
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder and the most common type of dementia. AD is characterized by a decline of cognitive function and brain atrophy, and is highly heritable with estimated heritability ranging from 60 to 80[Formula: see text]. The most straightforward and widely used strategy to identify AD genetic basis is to perform genome-wide association study (GWAS) of the case-control diagnostic status. These GWAS studies have identified over 50 AD related susceptibility loci. Recently, imaging genetics has emerged as a new field where brain imaging measures are studied as quantitative traits to detect genetic factors. Given that many imaging genetics studies did not involve the diagnostic outcome in the analysis, the identified imaging or genetic markers may not be related or specific to the disease outcome.
Results: We propose a novel method to identify disease-related genetic variants enriched by imaging endophenotypes, which are the imaging traits associated with both genetic factors and disease status. Our analysis consists of three steps: (1) map the effects of a genetic variant (e.g., single nucleotide polymorphism or SNP) onto imaging traits across the brain using a linear regression model, (2) map the effects of a diagnosis phenotype onto imaging traits across the brain using a linear regression model, and (3) detect SNP-diagnosis association via correlating the SNP effects with the diagnostic effects on the brain-wide imaging traits. We demonstrate the promise of our approach by applying it to the Alzheimer's Disease Neuroimaging Initiative database. Among 54 AD related susceptibility loci reported in prior large-scale AD GWAS, our approach identifies 41 of those from a much smaller study cohort while the standard association approaches identify only two of those. Clearly, the proposed imaging endophenotype enriched approach can reveal promising AD genetic variants undetectable using the traditional method.
Conclusion: We have proposed a novel method to identify AD genetic variants enriched by brain-wide imaging endophenotypes. This approach can not only boost detection power, but also reveal interesting biological pathways from genetic determinants to intermediate brain traits and to phenotypic AD outcomes.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies